0001209191-20-063474.txt : 20201215 0001209191-20-063474.hdr.sgml : 20201215 20201215162434 ACCESSION NUMBER: 0001209191-20-063474 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20201211 FILED AS OF DATE: 20201215 DATE AS OF CHANGE: 20201215 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Polymeropoulos Mihael Hristos CENTRAL INDEX KEY: 0001355537 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34186 FILM NUMBER: 201389838 MAIL ADDRESS: STREET 1: 9605 MEDICAL CENTER DRIVE SUITE 300 CITY: ROCKVILLE STATE: MD ZIP: 20850 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001347178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030491827 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 BUSINESS PHONE: 202-734-3400 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-12-11 0 0001347178 Vanda Pharmaceuticals Inc. VNDA 0001355537 Polymeropoulos Mihael Hristos 2200 PENNSYLVANIA AVENUE SUITE 300E WASHINGTON DC 20037 1 1 0 0 President and CEO Common Stock 2020-12-11 4 M 0 41817 8.75 A 1320816 D Common Stock 2020-12-11 4 S 0 35053 12.8765 D 1285763 D Common Stock 2020-12-14 4 M 0 61520 8.75 A 1347283 D Common Stock 2020-12-14 4 S 0 51049 13.1894 D 1296234 D Common Stock 2020-12-15 4 M 0 46663 8.75 A 1342897 D Common Stock 2020-12-15 4 S 0 39150 12.9973 D 1303747 D Employee Stock Option (Right to Buy) 8.75 2020-12-11 4 M 0 41817 0.00 D 2020-12-15 Common Stock 41817 108183 D Employee Stock Option (Right to Buy) 8.75 2020-12-14 4 M 0 61520 0.00 D 2020-12-15 Common Stock 61520 46663 D Employee Stock Option (Right to Buy) 8.75 2020-12-15 4 M 0 46663 0.00 D 2020-12-15 Common Stock 46663 0 D Represents shares of the Issuer's common stock sold to satisfy the exercise price and certain tax obligations relating to the acquisition of shares of the Issuer's common stock in connection with the exercise of certain stock options, which were scheduled to expire December 15, 2020 as reflected in this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.80 to $13.29, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.15 to $13.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.85 to $13.09, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4. The option vested in 48 equal monthly installments from the date of grant. /s/ Mihael Polymeropoulos 2020-12-15